PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 330.50
Bid: 331.50
Ask: 332.00
Change: 3.00 (0.92%)
Spread: 0.50 (0.151%)
Open: 332.00
High: 336.00
Low: 321.00
Prev. Close: 327.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-close trading update

14 Feb 2022 07:00

RNS Number : 5034B
Synthomer PLC
14 February 2022
 

14th February 2022

 

Synthomer Plc

 

Pre-close trading update

 

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the year ended 31st December 2021 ahead of announcing Full Year results on 3rd March 2022.

 

The Group has seen strong trading across all divisions during 2021 with Full Year EBITDA expected to be double the prior year, in-line with current market expectations of £518.4m* (2020: £259.4m; 2019: £177.9m).

 

Alongside a positive contribution from Omnova and strong organic growth, the exceptional performance in 2021 has benefited from peak margins within Performance Elastomers' NBR business.

 

As anticipated, NBR margins have now normalised to pre-Covid levels, although this has happened since January, ahead of Q1 2022 guidance set out in our Q3 2021 trading update. Accordingly, the Group does not expect any NBR pandemic premium in 2022.

 

In addition, year-to-date NBR demand has continued to be subdued due to high inventory levels of medical gloves and reduced demand due to the easing of the Covid19 pandemic. Trading conditions in NBR are expected to normalise by the end of H1 with market growth returning to 2019 levels in the second half.

 

All other divisions have had an encouraging start to the year, and the Group remains on track to complete the acquisition of Eastman's Adhesives Resins business in Q1. The Group continues to look for further bolt-on acquisition opportunities geared towards attractive end-markets that are value accretive to Synthomer's portfolio.

 

The Board remains confident that the benefits of recent acquisitions, continued investment in new capacity and its proven growth strategy will underpin growing sustainable profits in the coming years.

 

Further information will be provided on 3rd March with the Group's Full Year 2021 results.

 

* Teneo compiled consensus

- ENDS -

 

Conference call

 

The company will hold a conference call for investors and analysts at 0730 BST today:

 

Dial in number: +44 333 300 0804

Access code: 82084027#

 

Enquiries

 

Tim Hughes, President, Corporate Development Tel: +44 1279 436211 

Charles Armitstead, Teneo Tel: +44 7703 330 269

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFZGMZRMLGZZM
Date   Source Headline
8th Mar 20184:39 pmRNSDirector/PDMR Shareholding
8th Mar 20184:37 pmRNSDirector/PDMR Shareholding
5th Mar 20182:43 pmRNSDirector/PDMR Shareholding
1st Mar 20187:00 amRNSResults for the year ended 31 December 2017
12th Feb 201810:27 amRNSDirector Declaration
1st Feb 20187:00 amRNSCompletion of the acquisition of BASF Pischelsdorf
2nd Jan 20187:00 amRNSDisposal of Synthomer Leuna Gmbh facility
13th Dec 20172:55 pmRNSDirector Declaration
4th Dec 20175:31 pmRNSHolding(s) in Company
27th Nov 20179:29 amRNSHolding(s) in Company
10th Nov 20179:40 amRNSDirectorate Change
9th Nov 201710:03 amRNSDirector/PDMR Shareholding
6th Nov 20177:00 amRNSQ3 Trading update
9th Oct 20179:23 amRNSDirector Declaration
28th Sep 20177:00 amRNSAcquisition of BASF Pischelsdorf
18th Sep 20172:00 pmRNSHolding(s) in Company
17th Aug 201712:54 pmRNSHolding(s) in Company
8th Aug 20177:00 amRNSInterim Results for the 6 months ended 30 Jun 2017
1st Aug 20173:57 pmRNSHolding(s) in Company
10th Jul 201710:33 amRNSDirector/PDMR Shareholding
9th Jun 20173:14 pmRNSDirector/PDMR Shareholding
8th May 201712:40 pmRNSDirector/PDMR Shareholding
8th May 201712:24 pmRNSDirector/PDMR Shareholding
27th Apr 20174:05 pmRNSDirector Declaration
27th Apr 20172:53 pmRNSResult of AGM
27th Apr 20177:00 amRNSQ1 Trading update
27th Mar 20179:54 amRNSAnnual Financial Report
6th Mar 20177:02 amRNSAcquisition of Perstorp Belgium
6th Mar 20177:00 amRNSFinal Results
23rd Feb 20174:31 pmRNSAmendment TR-1 notification
8th Feb 20174:13 pmRNSHolding(s) in Company
6th Feb 201711:48 amRNSHolding(s) in Company
20th Jan 20177:00 amRNSQ4 and FY trading update
13th Dec 201610:57 amRNSHolding(s) in Company
1st Dec 20167:00 amRNSCapital Markets Day
28th Nov 20169:51 amRNSHolding(s) in Company
18th Nov 20164:56 pmRNSHolding(s) in Company
16th Nov 201610:15 amRNSHolding(s) in Company
10th Nov 20162:23 pmRNSHolding(s) in Company
9th Nov 20164:18 pmRNSDirector/PDMR Shareholding
9th Nov 20167:00 amRNSQ3 Trading update
3rd Oct 20162:11 pmRNSHolding(s) in Company
26th Sep 20169:25 amRNSHolding(s) in Company
14th Sep 20163:10 pmRNSHolding(s) in Company
14th Sep 20163:01 pmRNSHolding(s) in Company
11th Aug 20161:15 pmRNSDisposal
9th Aug 20167:00 amRNSInterim Results for six months ended 30 June 2016
7th Jul 201611:50 amRNSHolding(s) in Company
7th Jul 201610:28 amRNSDirector/PDMR Shareholding
5th Jul 201611:57 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.